TORCH-Plus-DZHK21
Study information
TORCH-Plus-DZHK21
- Recruiting status
-
Recruiting ongoing
- Recruitment start
08/2020
- Patients
4340
- Clinical Trials Registration
- Category
Registry
- DZHK Funding
EUR 3.169.463,16
Operative contact:
Main study centre - Farbod Sedaghat-Hamedani, MD
Torch.Register@med.uni-heidelberg.de
Johannes Trebing, MD
johannes.trebing@med.uni-heidelberg.de
TranslatiOnal Registry for CardiomyopatHies-Plus (TORCH-Plus-DZHK21)
The overarching aim of TORCH-Plus is to create a large-scale prospective data & biomaterial repository of patients with non-ischemic cardiomyopathies (CMP). The scientists want to study clinical outcomes, familial structures, phenotype-genotype associations, autoimmunity, and inflammatory mechanisms as well as gender-related aspects. By long-term follow-up and systematic evaluation of CMP-related mechanisms, TORCH-Plus aims to identify and validate novel risk stratification algorithms to improve the outcome of patients ultimately.
Publications
Translational Registry for Cardiomyopathies (Torch) – Rationale and First Results. Seyler, C. et al. ESC heart failure, (2017).
All publications of this trial can be found here
Principal Investigators
Principal investigator: Benjamin Meder (Heidelberg)
Study recruitment is available in these cities
The map only displays recruitment locations within Germany.